Harrow today announced new market access achievements in the 2025 Medicare Part D Prescription Drug Program.According to the company, effective January 1, 2025, cyclosporine ophthalmic solution 0.1% (Vevye) will be included on key formularies managed by major plan sponsors, including Express Scripts, Cigna, Kaiser Permanente, and CVS Caremark. Collectively, these plan sponsors … [Read more...] about Harrow announces expanded market access for cyclosporine ophthalmic solution in 2025 Medicare Part D Program
News
Study explores the true costs of treating pediatric cataracts
Reviewed by Vinita Rangroo Thrane, MD, PhD; Alexander S. Thrane, MD, PhD, FEBOphth; and Nils-Erik Boonstra, MDPediatric cataracts are a leading cause of reversible childhood blindness, but economic constraints make treatment challenging for many patients worldwide. In a presentation at the 42nd Congress of the European Society of Cataract and Refractive Surgeons, Vinita Rangroo … [Read more...] about Study explores the true costs of treating pediatric cataracts
Management of persistent exudative retinal detachment: exploring etiology and surgical outcomes
This report aims to present the causes, clinical features, and surgical outcomes of persistent exudative retinal detachment (ERD) in a single tertiary referral center experience. … [Read more...] about Management of persistent exudative retinal detachment: exploring etiology and surgical outcomes
Evaluation of ocular surface inflammation and systemic conditions in patients with systemic lupus erythematosus: a cross-sectional study
The cross-sectional study was designed to evaluate the association of ocular surface inflammation with systemic conditions in patients with systemic lupus erythematosus (SLE). … [Read more...] about Evaluation of ocular surface inflammation and systemic conditions in patients with systemic lupus erythematosus: a cross-sectional study
Evaluation of pseudoexfoliation syndrome patients with systemic immune indexes
The aim of this study was to investigate the level of peripheral blood systemic immune indexes in pseudoexfoliation syndrome (PXS) patients and to compare the results with healthy controls. … [Read more...] about Evaluation of pseudoexfoliation syndrome patients with systemic immune indexes
Is retinal vein occlusion highly associated with an increased risk of myocardial infarction? A systematic review and meta-analysis
Schorr EM, Rossi KC, Stein LK, Park BL, Tuhrim S, Dhamoon MS. Characteristics and Outcomes of Retinal Artery Occlusion: Nationally Representative Data, (in eng). Stroke. 2020;51(3):800–807.https://doi.org/10.1161/strokeaha.119.027034.Hwang DD, et al. Incidence of retinal artery occlusion and related mortality in Korea, 2005 to 2018, (in eng). JAMA Netw Open. 2023;6(3):e233068. … [Read more...] about Is retinal vein occlusion highly associated with an increased risk of myocardial infarction? A systematic review and meta-analysis
A clinical study on the therapeutic effects of 577 nm micropulse laser photocoagulation treatment in early-stage CSCR patients
To research the therapeutic effects of 577 nm micropulse laser photocoagulation (MLP) treatment in early-stage central serous chorioretinopathy (CSCR) patients. … [Read more...] about A clinical study on the therapeutic effects of 577 nm micropulse laser photocoagulation treatment in early-stage CSCR patients
VIDEO: Consider epithelial thickness mapping during refractive cataract surgery planning
November 11, 2024 2 min watch NEW YORK — In this Healio Video Perspective from OSN New York, John P. Berdahl, MD, shares pearls on how to decide between LASIK or PRK for patients who previously underwent cataract surgery. While LASIK traditionally shows better outcomes for these patients, Berdahl recommends that ophthalmologists incorporate epithelial thickness mapping … [Read more...] about VIDEO: Consider epithelial thickness mapping during refractive cataract surgery planning
AlloVir to merge with Kalaris Therapeutics
November 11, 2024 1 min read AlloVir, an allogeneic T cell immunotherapy company, will merge with Kalaris Therapeutics to focus on retinal diseases, according to a press release. The merger is expected to close in the first quarter of 2025, with the combined company estimated to have about $100 million in cash to operate into the fourth quarter of 2026. The company, … [Read more...] about AlloVir to merge with Kalaris Therapeutics
VIDEO: Ocular Therapeutix shifts to retina-focused treatments
November 11, 2024 1 min watch CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Peter K. Kaiser, MD, of Ocular Therapeutix, discusses the company’s shift to a retina-focused program. Two phase 3 macular degeneration programs investigating Axpaxli, a sustained-release polymer that delivers a tyrosine kinase inhibitor, are underway at Ocular … [Read more...] about VIDEO: Ocular Therapeutix shifts to retina-focused treatments